Published in J Neurochem on January 08, 2007
Comparison of analytical mathematical approaches for identifying key nuclear magnetic resonance spectroscopy biomarkers in the diagnosis and assessment of clinical change of diseases. J Comp Neurol (2010) 1.71
Energy deficit in Huntington disease: why it matters. J Clin Invest (2011) 1.51
Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease. PLoS One (2012) 1.31
Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status. Mov Disord (2010) 1.30
Cerebral metabolite abnormalities in human immunodeficiency virus are associated with cortical and subcortical volumes. J Neurovirol (2010) 1.22
Neurochemical changes in the rat prefrontal cortex following acute phencyclidine treatment: an in vivo localized (1)H MRS study. NMR Biomed (2009) 1.08
Early alterations of brain cellular energy homeostasis in Huntington disease models. J Biol Chem (2011) 1.05
Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: interactions between neurons and astrocytes. Basal Ganglia (2012) 1.02
ROC-supervised principal component analysis in connection with the diagnosis of diseases. Am J Transl Res (2011) 1.00
Initial in vivo rodent sodium and proton MR imaging at 21.1 T. Magn Reson Imaging (2010) 1.00
R6/2 Huntington's disease mice develop early and progressive abnormal brain metabolism and seizures. J Neurosci (2012) 0.98
Modeling kinetics of subcellular disposition of chemicals. Chem Rev (2009) 0.96
The Unexpected Uses of Urso- and Tauroursodeoxycholic Acid in the Treatment of Non-liver Diseases. Glob Adv Health Med (2014) 0.94
Application of clustering analyses to the diagnosis of Huntington disease in mice and other diseases with well-defined group boundaries. Comput Methods Programs Biomed (2011) 0.94
In vivo monitoring of recovery from neurodegeneration in conditional transgenic SCA1 mice. Exp Neurol (2011) 0.92
Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease. J Cereb Blood Flow Metab (2011) 0.91
Acamprosate reduces ethanol drinking behaviors and alters the metabolite profile in mice lacking ENT1. Neurosci Lett (2010) 0.90
Homeostatic adaptations in brain energy metabolism in mouse models of Huntington disease. J Cereb Blood Flow Metab (2012) 0.86
Corticostriatal dysfunction underlies diminished striatal ascorbate release in the R6/2 mouse model of Huntington's disease. Brain Res (2009) 0.85
Impaired brain creatine kinase activity in Huntington's disease. Neurodegener Dis (2010) 0.84
Metabolic disturbances in diseases with neurological involvement. Aging Dis (2013) 0.84
Proton MR spectroscopy-detectable major neurotransmitters of the brain: biology and possible clinical applications. AJNR Am J Neuroradiol (2011) 0.83
Probing the metabolic aberrations underlying mutant huntingtin toxicity in yeast and assessing their degree of preservation in humans and mice. J Proteome Res (2010) 0.81
Up-regulation of GLT1 reverses the deficit in cortically evoked striatal ascorbate efflux in the R6/2 mouse model of Huntington's disease. J Neurochem (2012) 0.80
Magnetic resonance spectroscopy of regional brain metabolite markers in FALS mice and the effects of dietary creatine supplementation. Eur J Neurosci (2009) 0.78
Region-specific changes in ascorbate concentration during rat brain development quantified by in vivo (1)H NMR spectroscopy. NMR Biomed (2010) 0.78
Preclinical (1)H-MRS neurochemical profiling in neurological and psychiatric disorders. Bioanalysis (2012) 0.78
Cuprizone-induced demyelination and demyelination-associated inflammation result in different proton magnetic resonance metabolite spectra. NMR Biomed (2015) 0.78
Dysregulation of system xc(-) expression induced by mutant huntingtin in a striatal neuronal cell line and in R6/2 mice. Neurochem Int (2014) 0.77
HdhQ111 Mice Exhibit Tissue Specific Metabolite Profiles that Include Striatal Lipid Accumulation. PLoS One (2015) 0.76
Does closure of acid-sensing ion channels reduce ischemia/reperfusion injury in the rat brain? Neural Regen Res (2013) 0.76
The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain. PLoS One (2017) 0.75
Dysregulation of corticostriatal ascorbate release and glutamate uptake in transgenic models of Huntington's disease. Antioxid Redox Signal (2013) 0.75
Measurement of Total Antioxidant Capacity in Sub-μL Blood Samples Using Craft Paper-based Analytical Devices. RSC Adv (2015) 0.75
Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med (1993) 15.51
Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell (1996) 12.59
Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol (1985) 7.93
Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet (1993) 6.53
Automatic, localized in vivo adjustment of all first- and second-order shim coils. Magn Reson Med (1993) 5.48
In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time. Magn Reson Med (1999) 4.26
Mitochondria take center stage in aging and neurodegeneration. Ann Neurol (2005) 3.83
Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci (1993) 3.79
Field mapping without reference scan using asymmetric echo-planar techniques. Magn Reson Med (2000) 3.13
Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology (2004) 2.81
Fine structural localization of glutamine synthetase in astrocytes of rat brain. Brain Res (1979) 2.62
Toward an in vivo neurochemical profile: quantification of 18 metabolites in short-echo-time (1)H NMR spectra of the rat brain. J Magn Reson (1999) 2.42
Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep (2004) 2.35
Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature (1986) 2.29
Highly resolved in vivo 1H NMR spectroscopy of the mouse brain at 9.4 T. Magn Reson Med (2004) 2.25
Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport (1996) 2.18
Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum Mol Genet (2002) 2.17
Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci U S A (2000) 2.00
HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet (2005) 1.96
Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J Neurophysiol (2001) 1.91
Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology (1993) 1.88
Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med (1999) 1.86
Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci U S A (1992) 1.86
Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J Nucl Med (2006) 1.83
Assessment of adrenoleukodystrophy lesions by high field MRS in non-sedated pediatric patients. Neurology (2005) 1.73
Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol Dis (2001) 1.71
Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain (2002) 1.71
Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J Biol Chem (2005) 1.67
Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. Trends Neurosci (2004) 1.58
Developmental and regional changes in the neurochemical profile of the rat brain determined by in vivo 1H NMR spectroscopy. Magn Reson Med (2003) 1.57
Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol (1997) 1.53
Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol (2000) 1.49
Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol (2000) 1.47
Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem (1993) 1.24
Characterization of the major brain osmolytes that accumulate in salt-loaded rats. Am J Physiol (1989) 1.21
Taurine and neural cell damage. Amino Acids (2000) 1.20
1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology (1998) 1.20
Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J Neurochem (2000) 1.19
Huntingtin and its role in neuronal degeneration. Neuroscientist (2004) 1.16
Clinical correlation of striatal 1H MRS changes in Huntington's disease. Neurology (1999) 1.15
Metabolic characterization of the R6/2 transgenic mouse model of Huntington's disease by high-resolution MAS 1H NMR spectroscopy. J Proteome Res (2006) 1.08
In vivo effect of chronic hypoxia on the neurochemical profile of the developing rat hippocampus. Brain Res Dev Brain Res (2005) 1.07
Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory. Mov Disord (1996) 1.06
The role of taurine in the central nervous system and the modulation of intracellular calcium homeostasis. Neurochem Res (2002) 1.06
Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. J Neurochem (2005) 1.04
N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice. Neuroreport (2000) 1.01
N-acetylaspartate: a literature review of animal research on brain ischaemia. J Neurochem (2004) 1.01
Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology (1998) 0.97
Proton MRS in neurological disorders. Eur J Radiol (1999) 0.95
Metabolic changes in quinolinic acid-lesioned rat striatum detected non-invasively by in vivo (1)H NMR spectroscopy. J Neurosci Res (2001) 0.94
Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and gamma-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases. J Neurol Sci (1985) 0.91
Polyglutamine expansion inhibits respiration by increasing reactive oxygen species in isolated mitochondria. Biochem Biophys Res Commun (2006) 0.91
Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease. J Neurol Sci (2005) 0.90
Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: a proton magnetic resonance spectroscopy study. J Neurol Neurosurg Psychiatry (1997) 0.89
Huntington disease: clinical, genetic, and social aspects. J Geriatr Psychiatry Neurol (1998) 0.89
Predictors of neuropathological severity in 100 patients with Huntington's disease. Ann Neurol (2003) 0.88
From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease. Philos Trans R Soc Lond B Biol Sci (1999) 0.86
Decreased brain N-acetylaspartate in Huntington's disease. Brain Res (1992) 0.85
Serial 1H-NMR spectroscopy study of metabolic impairment in primates chronically treated with the succinate dehydrogenase inhibitor 3-nitropropionic acid. Neurobiol Dis (1999) 0.83
New magnetic resonance spectroscopy biomarker for monitoring neurodegenerative diseases: animal models. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2005) 0.82
Ascorbate-induced oxidative inactivation of Zn2+-glycerophosphocholine cholinephosphodiesterase. J Neurochem (1998) 0.82
Proton magnetic resonance spectroscopy of cerebrospinal fluid in neurodegenerative disease: indication of glial energy impairment in Huntington chorea, but not Parkinson disease. J Neurosci Res (2000) 0.82
CSF and serum metabolic profile of patients with Huntington's chorea: a study by high resolution proton NMR spectroscopy and HPLC. Neurosci Lett (1993) 0.81
Cerebral cation shifts and amino acids in Huntington's disease. Arch Neurol (1986) 0.80
Immunocytochemical localization of cysteine sulfinate decarboxylase in astrocytes in the cerebellum and hippocampus: a quantitative double immunofluorescence study with glial fibrillary acidic protein and S-100 protein. Neuroscience (1996) 0.79
Effect of chronic hypernatremic dehydration and rapid rehydration on brain carbohydrate, energy, and amino acid metabolism in weanling mice. J Neurochem (1983) 0.77
Insulin and brain metabolism. Absence of direct action of insulin on K+ and Na+ transport in normal rabbit brain. Diabetes (1977) 0.77
Glycerophosphorylcholine phosphocholine phosphodiesterase activity in cultured oligodendrocytes, astrocytes, and central nervous tissue of dysmyelinating rodent mutants. J Neurosci Res (1992) 0.76
Pluripotency of mesenchymal stem cells derived from adult marrow. Nature (2002) 19.57
Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci U S A (2010) 3.58
Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. Exp Neurol (2002) 2.72
Ultrahigh field magnetic resonance imaging and spectroscopy. Magn Reson Imaging (2003) 2.34
In vivo 1H NMR spectroscopy of the human brain at high magnetic fields: metabolite quantification at 4T vs. 7T. Magn Reson Med (2009) 2.27
Highly resolved in vivo 1H NMR spectroscopy of the mouse brain at 9.4 T. Magn Reson Med (2004) 2.25
MP2RAGE, a self bias-field corrected sequence for improved segmentation and T1-mapping at high field. Neuroimage (2009) 2.22
Transplantation of a novel cell line population of umbilical cord blood stem cells ameliorates neurological deficits associated with ischemic brain injury. Stem Cells Dev (2005) 2.07
Neuroglial metabolism in the awake rat brain: CO2 fixation increases with brain activity. J Neurosci (2004) 2.04
Temperature and SAR calculations for a human head within volume and surface coils at 64 and 300 MHz. J Magn Reson Imaging (2004) 2.01
MR spectroscopy of the human brain with enhanced signal intensity at ultrashort echo times on a clinical platform at 3T and 7T. Magn Reson Med (2009) 1.93
Retracted Marker-independent identification of glioma-initiating cells. Nat Methods (2010) 1.84
Sustained neuronal activation raises oxidative metabolism to a new steady-state level: evidence from 1H NMR spectroscopy in the human visual cortex. J Cereb Blood Flow Metab (2006) 1.73
Perinatal iron deficiency alters the neurochemical profile of the developing rat hippocampus. J Nutr (2003) 1.71
Comparison of analytical mathematical approaches for identifying key nuclear magnetic resonance spectroscopy biomarkers in the diagnosis and assessment of clinical change of diseases. J Comp Neurol (2010) 1.71
Calcium-induced cytochrome c release from CNS mitochondria is associated with the permeability transition and rupture of the outer membrane. J Neurochem (2002) 1.70
Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. Stem Cells Dev (2008) 1.65
Effect of hypoglycemia on brain glycogen metabolism in vivo. J Neurosci Res (2003) 1.64
N-acetylcysteine normalizes neurochemical changes in the glutathione-deficient schizophrenia mouse model during development. Biol Psychiatry (2011) 1.59
Effect of deep pentobarbital anesthesia on neurotransmitter metabolism in vivo: on the correlation of total glucose consumption with glutamatergic action. J Cereb Blood Flow Metab (2002) 1.58
Developmental and regional changes in the neurochemical profile of the rat brain determined by in vivo 1H NMR spectroscopy. Magn Reson Med (2003) 1.57
On the origin of the MR image phase contrast: an in vivo MR microscopy study of the rat brain at 14.1 T. Neuroimage (2009) 1.56
Clinical proton MR spectroscopy in central nervous system disorders. Radiology (2014) 1.53
Stem cells for ischemic brain injury: a critical review. J Comp Neurol (2009) 1.53
Thymidine analogs are transferred from prelabeled donor to host cells in the central nervous system after transplantation: a word of caution. Stem Cells (2005) 1.51
Measurement of reduced glutathione (GSH) in human brain using LCModel analysis of difference-edited spectra. Magn Reson Med (2003) 1.49
De novo induction of genetically engineered brain tumors in mice using plasmid DNA. Cancer Res (2009) 1.49
Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene. Mol Ther (2004) 1.44
Neuroscience in middle schools: a professional development and resource program that models inquiry-based strategies and engages teachers in classroom implementation. CBE Life Sci Educ (2006) 1.43
Orbital neoplasms in adults: clinical, radiologic, and pathologic review. Radiographics (2013) 1.35
Localized short-echo-time proton MR spectroscopy with full signal-intensity acquisition. Magn Reson Med (2006) 1.35
Prospective and retrospective motion correction in diffusion magnetic resonance imaging of the human brain. Neuroimage (2011) 1.34
Direct in vivo measurement of human cerebral GABA concentration using MEGA-editing at 7 Tesla. Magn Reson Med (2002) 1.31
Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci U S A (2002) 1.29
Feasibility of in vivo 15N MRS detection of hyperpolarized 15N labeled choline in rats. Phys Chem Chem Phys (2010) 1.28
Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. Proc Natl Acad Sci U S A (2003) 1.27
Brain glucose concentrations in patients with type 1 diabetes and hypoglycemia unawareness. J Neurosci Res (2004) 1.27
Toward dynamic isotopomer analysis in the rat brain in vivo: automatic quantitation of 13C NMR spectra using LCModel. NMR Biomed (2003) 1.27
Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy. J Neurooncol (2006) 1.27
Sensitivity of single-voxel 1H-MRS in investigating the metabolism of the activated human visual cortex at 7 T. Magn Reson Imaging (2006) 1.27
In vivo 13C NMR spectroscopy and metabolic modeling in the brain: a practical perspective. Magn Reson Imaging (2006) 1.25
Neuroprotective role of lactate after cerebral ischemia. J Cereb Blood Flow Metab (2009) 1.24
In vivo assessment of myelination by phase imaging at high magnetic field. Neuroimage (2011) 1.23
Proton T2 relaxation time of J-coupled cerebral metabolites in rat brain at 9.4 T. NMR Biomed (2008) 1.23
1H NMR spectroscopy of rat brain in vivo at 14.1Tesla: improvements in quantification of the neurochemical profile. J Magn Reson (2008) 1.22
Cerebellar cortical layers: in vivo visualization with structural high-field-strength MR imaging. Radiology (2010) 1.21
Increased susceptibility of striatal mitochondria to calcium-induced permeability transition. J Neurosci (2003) 1.20
Detection of an antioxidant profile in the human brain in vivo via double editing with MEGA-PRESS. Magn Reson Med (2006) 1.19
Neuroprotection by a bile acid in an acute stroke model in the rat. J Cereb Blood Flow Metab (2002) 1.19
Proton-observed carbon-edited NMR spectroscopy in strongly coupled second-order spin systems. Magn Reson Med (2006) 1.18
In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. J Immunother (2007) 1.18
Direct, noninvasive measurement of brain glycogen metabolism in humans. Neurochem Int (2003) 1.18
In vivo 13C NMR assessment of brain glycogen concentration and turnover in the awake rat. Neurochem Int (2003) 1.17
Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I. Neurobiol Dis (2011) 1.14
Therapeutic targets in prostaglandin E2 signaling for neurologic disease. Curr Med Chem (2008) 1.14
Apoptosis-associated microRNAs are modulated in mouse, rat and human neural differentiation. BMC Genomics (2010) 1.12
Proton NMR of (15)N-choline metabolites enhanced by dynamic nuclear polarization. J Am Chem Soc (2009) 1.12
Infusion of human umbilical cord blood ameliorates neurologic deficits in rats with hemorrhagic brain injury. Ann N Y Acad Sci (2005) 1.11
ELISA for human serum leucine-rich alpha-2-glycoprotein-1 employing cytochrome c as the capturing ligand. J Immunol Methods (2008) 1.09
Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: detection of high GABA concentrations. Magn Reson Med (2006) 1.09
Human brain glycogen content and metabolism: implications on its role in brain energy metabolism. Am J Physiol Endocrinol Metab (2006) 1.08
Compartmentalized Cerebral Metabolism of [1,6-(13)C]Glucose Determined by in vivo (13)C NMR Spectroscopy at 14.1 T. Front Neuroenergetics (2011) 1.08
Dynamic or inert metabolism? Turnover of N-acetyl aspartate and glutathione from D-[1-13C]glucose in the rat brain in vivo. J Neurochem (2004) 1.08
In vivo detection of brain Krebs cycle intermediate by hyperpolarized magnetic resonance. J Cereb Blood Flow Metab (2012) 1.07
In vivo effect of chronic hypoxia on the neurochemical profile of the developing rat hippocampus. Brain Res Dev Brain Res (2005) 1.07
High-resolution magnetic resonance imaging quantitatively detects individual pancreatic islets. Diabetes (2011) 1.06
Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: application to schizophrenia. MAGMA (2005) 1.06
Neural differentiation and incorporation of bone marrow-derived multipotent adult progenitor cells after single cell transplantation into blastocyst stage mouse embryos. Cell Transplant (2003) 1.05
Characterization of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human stem cell and gene therapy. Brain Res Bull (2007) 1.04
Brain glucose concentrations in healthy humans subjected to recurrent hypoglycemia. J Neurosci Res (2005) 1.04
Biochemical quantification of total brain glycogen concentration in rats under different glycemic states. Neurochem Int (2006) 1.03
Apoptosis in transgenic mice expressing the P301L mutated form of human tau. Mol Med (2008) 1.03
Bile acids and apoptosis modulation: an emerging role in experimental Alzheimer's disease. Trends Mol Med (2008) 1.03
1H NMR detection of vitamin C in human brain in vivo. Magn Reson Med (2004) 1.02
Chronic cortical and subcortical pathology with associated neurological deficits ensuing experimental herpes encephalitis. Brain Pathol (2009) 1.02
In vivo enzymatic activity of acetylCoA synthetase in skeletal muscle revealed by (13)C turnover from hyperpolarized [1-(13)C]acetate to [1-(13)C]acetylcarnitine. Biochim Biophys Acta (2013) 1.02
Scavenging free radicals to preserve enhancement and extend relaxation times in NMR using dynamic nuclear polarization. Angew Chem Int Ed Engl (2010) 1.02
Two pathways for tBID-induced cytochrome c release from rat brain mitochondria: BAK- versus BAX-dependence. J Neurochem (2003) 1.01
Human finger somatotopy in areas 3b, 1, and 2: a 7T fMRI study using a natural stimulus. Hum Brain Mapp (2012) 1.01
Quantitative proton spectroscopic imaging of the neurochemical profile in rat brain with microliter resolution at ultra-short echo times. Magn Reson Med (2008) 1.01
ROC-supervised principal component analysis in connection with the diagnosis of diseases. Am J Transl Res (2011) 1.00
Effect of chronic hypoglycaemia on glucose concentration and glycogen content in rat brain: A localized 13C NMR study. J Neurochem (2006) 1.00
Unedited in vivo detection and quantification of γ-aminobutyric acid in the occipital cortex using short-TE MRS at 3 T. NMR Biomed (2013) 0.99
The neurochemical profile quantified by in vivo 1H NMR spectroscopy. Neuroimage (2011) 0.99
Perinatal iron deficiency predisposes the developing rat hippocampus to greater injury from mild to moderate hypoxia-ischemia. J Cereb Blood Flow Metab (2006) 0.99
Evolution of the neurochemical profile after transient focal cerebral ischemia in the mouse brain. J Cereb Blood Flow Metab (2009) 0.99
Dynamics of lactate concentration and blood oxygen level-dependent effect in the human visual cortex during repeated identical stimuli. J Neurosci Res (2007) 0.99
1H-localized broadband 13C NMR spectroscopy of the rat brain in vivo at 9.4 T. Magn Reson Med (2003) 0.98
Cytochrome C release from CNS mitochondria and potential for clinical intervention in apoptosis-mediated CNS diseases. Antioxid Redox Signal (2005) 0.98
Detection of neuronal loss using T(1rho) MRI assessment of (1)H(2)O spin dynamics in the aphakia mouse. J Neurosci Methods (2008) 0.98
Caffeine consumption attenuates neurochemical modifications in the hippocampus of streptozotocin-induced diabetic rats. J Neurochem (2009) 0.97
Tauroursodeoxycholic acid improves the survival and function of nigral transplants in a rat model of Parkinson's disease. Cell Transplant (2002) 0.97
In vivo measurement of glycine with short echo-time 1H MRS in human brain at 7 T. MAGMA (2008) 0.97